The bill, identified as Substitute Senate Bill No. 241 with File No. 382, mandates that each entity covered by the federal 340B Drug Pricing Program must submit an annual report to the Health Systems Planning Unit of the Office of Health Strategy (OHS) by April 1, 2025, and annually thereafter. The report must include detailed information about the entity's participation in the program, such as the aggregated acquisition cost for prescription drugs, payment amounts received for these drugs, payments made to contract pharmacies, the number of claims, and the national drug code numbers for the fifty most frequently dispensed drugs if the entity is a hospital. Additionally, the report must describe programs and services funded by savings from the program that support community access to care and would not be sustainable without such savings. The information must be disaggregated by payer mix, including Medicare, Medicaid, and private insurance, as prescribed by the executive director of OHS.

The executive director of OHS is required to post a summary of the aggregate information received on the OHS website. The bill specifies that there is no fiscal impact to OHS as the additional workload is expected to be managed by existing staff. The bill's effective date is October 1, 2024, and it introduces a new section to the law. The bill was reported through Senator Anwar of the 3rd District, Chairperson of the Committee on Public Health, and recommended to pass by the Public Health Committee with a vote of 25 in favor and 11 against.